Entera Bio Ltd.
ENTX
$2.89
$0.020.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -100.00% | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 18.64% | -10.56% | 16.55% | 4.47% | 5.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.03% | 35.85% | 25.75% | 6.30% | 20.07% |
| Operating Income | -71.03% | -38.08% | -30.17% | -7.78% | -23.23% |
| Income Before Tax | -175.30% | -36.54% | -28.67% | -5.93% | -23.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.30% | -36.54% | -27.91% | -5.93% | -23.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.30% | -36.54% | -27.91% | -5.93% | -23.82% |
| EBIT | -71.03% | -38.08% | -30.17% | -7.78% | -23.23% |
| EBITDA | -71.14% | -38.24% | -30.48% | -7.91% | -23.54% |
| EPS Basic | -155.56% | -23.99% | -5.80% | 15.32% | 1.90% |
| Normalized Basic EPS | -155.93% | -24.05% | -6.40% | 15.34% | 1.94% |
| EPS Diluted | -155.56% | -23.99% | -5.80% | 15.32% | 1.90% |
| Normalized Diluted EPS | -155.93% | -24.05% | -6.40% | 15.34% | 1.94% |
| Average Basic Shares Outstanding | 7.72% | 10.10% | 20.88% | 25.09% | 26.28% |
| Average Diluted Shares Outstanding | 7.72% | 10.10% | 20.88% | 25.09% | 26.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |